TB-500 Explained: Evidence, Mechanism, and Dosing Reality

Is TB-500 FDA approved?

No. The article does not describe TB-500 as approved for any use; it notes no completed human trials exist and it is sold for research purposes only.

What is the TB-500 dosage for humans?

There are no validated human dosing protocols. Circulating protocols of roughly 2 to 5 mg twice weekly are inferences scaled from animal studies, not clinical pharmacology.

Is TB-500 better than BPC-157?

Neither has a meaningful clinical advantage; both are preclinical compounds with animal data but no human RCTs, according to the article.

Does TB-500 have side effects or safety risks?

The article notes a theoretical oncogenic risk from TB-500's pro-angiogenic activity that has not been formally evaluated in long-term human studies, and pharmacokinetic gaps mean safety data is largely absent.

Is there any human evidence that TB-500 works?

The only completed human efficacy data is a Phase III trial of a topical 0.1% ophthalmic solution for a corneal disease, which is a different route, tissue, and dose than the injections used for musculoskeletal recovery.